| Test | Interval |
| HIV-related testing | |
| HIV serology | At baseline if there is no laboratory documentation of infection |
| CD4 cell count | At baseline Every 3 to 6 months (may be extended to ≥12 months in clinically stable patients on ART*) |
| HIV viral load | At baseline After ART initiation:
|
| Genotypic resistance testing | At baseline Prior to initiation of ART, if delayed (recommended in pregnant women; optional for others if performed at baseline visit) |
| HLA-B5701 testing | If considering use of abacavir |
| Tropism testing | If considering use of maraviroc |
| Cardiovascular risk factors | |
| Blood pressure check | At baseline and annually |
| Fasting glucose and/or hemoglobin A1c | At baseline 1 to 3 months following ART initiation or modification and then annually¶ |
| Fasting lipid profile | At baseline 1 to 3 months following ART initiation or modification and then every 6 to 12 months |
| Weight assessment | At baseline and follow-up visits |
| Tobacco use assessment | At baseline and annually |
| Other metabolic complications | |
| Bone densitometry | At baseline in postmenopausal women and men ≥50 years old Subsequent testing frequency depends on findings on baseline exam |
| Aortic aneurysm screening (abdominal ultrasonography) | Once in men 65 to 75 years old who have ever smoked |
| Neuropsychiatric disorders | |
| Depression screening | At baseline and annually |
| Screening for cognitive deficits | At baseline and annually |
| Cancers | |
| Colonoscopy | At 45 years old in asymptomatic patients at average risk Earlier screening may be warranted for those with strong family history of colon cancer Subsequent testing frequency depends on findings on baseline exam |
| Mammography | Annually in all women 50 to 74 years old |
| Cervical Pap smear (with or without HPV testing in women ≥30 years) | At baseline; interval for repeat testing depends on results and whether HPV co-testing was performedΔ Additional testing may be warranted for those with abnormal results |
| Anal Pap smear | Consider at baseline and annually More frequent or additional testing may be warranted for those with abnormal results |
| Other infections | |
| Syphilis serology | At baseline Annually for sexually active persons (or more frequently if at high risk) |
| Chlamydia and gonorrhea testing (at all sites of potential exposure) | At baseline Annually for sexually active persons (or more frequently if at high risk) |
| Trichomonas | At baseline for persons having vaginal sex Annually for sexually active persons who engage in vaginal sex |
| TB testing (TST or IGRA) | At baseline unless there is a history of a prior positive test Annually in patients at ongoing risk for TB unless there is a history of a prior positive test |
| HAV and HBV serologies | At baseline, with vaccination(s) in persons not immune |
| HCV serology, with reflex viral level for positive result | At baseline Annually in patients at risk (eg, injection drug users, men who have sex with men, transgender women) |
| Medication toxicity | |
| Complete blood count with differential | At baseline Complete blood count with differential every 3 to 6 months when monitoring CD4 count and every year once the CD4 count is no longer monitored |
| BUN and creatinineפ | At baseline 2 to 8 weeks after ART initiation and every 6 months thereafter |
| ALT, AST, and total bilirubin | At baseline 2 to 8 weeks after ART initiation and every 6 months thereafter |
| Urinalysis | At baseline After ART initiation or change Every 12 months on ART (every 6 months while on tenofovir disoproxil fumarate-containing regimens) |
| Dilated fundoscopic exam | Consider every 12 months in patients with CD4 cell count <50 cells/microL |
